Vulintus Receives NIH Phase II SBIR Funding for OptiSpeech

Written By Drew Sloan

The National Institute on Deafness and Other Communication Disorders awarded Vulintus $1.5M for a two-year Phase II SBIR project to run a multi-site efficacy study of the OptiSpeech system for speech therapy and to create commercial-ready beta systems. Holle Carey is the principal investigator.

Drew Sloan
Previous

Vulintus Heads to Chicago for SfN 2015
Next

Vulintus Starts On-Field Testing of NeuroTriage System